Hormonal
Post-diagnosis weight gain of >10 kg is associated with a 70% increase in all-cause mortality and a 78% increase in breast cancer-specific mortality compared to maintaining stable weight.
For breast cancer survivors, avoiding significant weight gain after diagnosis is critical for survival. The study shows that gaining more than 10kg after diagnosis significantly increases the risk of dying from breast cancer or other causes. Survivors should work with their care team to monitor weight and implement lifestyle changes to maintain a stable, healthy weight, as this is associated with improved mortality outcomes.
women who gained >10 kg had a 70% increase in all-cause mortality (95% CI, 1.21-2.41)... Breast cancer mortality increased by 78% among women who gained >10 kg between diagnosis and CWLS enrollment (95% CI, 1.01-3.14).
Why this rating
Large cohort study (n=3,993) with long follow-up and adjustment for multiple confounders, though observational design limits causal inference.
Source
Body Mass Index Before and After Breast Cancer Diagnosis: Associations with All-Cause, Breast Cancer, and Cardiovascular Disease Mortality
Hazel B. Nichols et al. · Cancer Epidemiology Biomarkers & Prevention · 2009
DOI 10.1158/1055-9965.epi-08-1094
More from this paper
- Post-diagnosis obesity (BMI >= 30 kg/m2) is associated with a 52% increase in all-cause mortality and a 2.28 times greater risk of breast cancer-specific mortality compared to normal BMI.Good
- Post-diagnosis weight loss of >10 kg is associated with a 2.66 times greater all-cause mortality compared to maintaining stable weight.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →